Find your next paid study

Multiple Myeloma Research ConsortiumNCT07053436

Glioblastoma (GBM)Newly Diagnosed GlioblastomaGBM+4 more

A Phase 2 Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Silevertinib, an Oral EGFR Inhibitor, in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter and EGFRvIII

The purpose of this study is to see if combining silevertinib with temozolomide after surgery and radiotherapy helps treat newly diagnosed glioblastoma (GBM) b…

Black Diamond Therapeutics, Inc.NCT07326566

~$10 – $8,750

Multiple MyelomaNewly Diagnosed Multiple Myeloma (NDMM)Relapsed and/or Refractory Multiple Myeloma (RRMM)

A Phase II Trial Evaluating 18F-Fluciclovine PET/CT in Multiple Myeloma

Background: Multiple myeloma (MM) is an incurable cancer of certain blood cells. MM often returns after treatment, and most people survive only 5 to 8 years a…

National Cancer Institute (NCI)NCT06103838

~$10 – $5,625

Observational

REMIND: An Investigator Initiated Study Testing the Feasibility of Maintenance Radiotherapy for Patients With Newly Diagnosed Glioblastoma

REMIND is a single-center feasibility study testing maintenance radiotherapy in adult patients with newly diagnosed glioblastoma. Participants will be consent…

GlioblastomaNewly Diagnosed GlioblastomaBrain Tumor

University of MinnesotaNCT07831772

~$10 – $6,250

Newly Diagnosed Glioblastoma

A Multi-Center, Randomized, Phase 2 Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab (GIANT)

GIANT is an open-label, multi-center, randomized, perioperative (neoadjuvant followed by adjuvant), phase 2 trial with a safety lead-in phase to investigate th…

Duke UniversityNCT06816927

~$10 – $6,250

Phase 1

A Phase 1b/2 Study of the Combination Isatuximab, Iberdomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible or Not Intended for Upfront Transplant

This study is to evaluate the combination of isatuximab, iberdomide, bortezomib, and dexamethasone in newly diagnosed multiple myeloma participants who are tra…

Newly Diagnosed Multiple Myeloma

Dana-Farber Cancer InstituteNCT07601100

Phase 1

A Phase 1 Study of Bispecific T Cell Engager (BRiTE) in Patients With Newly Diagnosed or Recurrent Glioblastoma

This Phase 1 study will assess the safety of a novel brain Bispecific T cell engager (BRiTE) in patients with newly diagnosed or recurrent World Health Organiz…

Newly Diagnosed GlioblastomaRecurrent Glioblastoma

Mustafa Khasraw, MBChB, MD, FRCP, FRACPNCT04903795

Phase 3

Phase III Open-Label, Randomised Study of Consolidation With AZD0120 (Dual-Targeting BCMA/CD19 CAR-T) vs Continuous Standard Therapy in NDMM Patients Ineligible for ASCT as Initial Therapy (DURGA-5)

This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of standard induction regimens (IsaVRd and …

Newly Diagnosed Multiple Myeloma

Newly Diagnosed Multiple Myeloma (NDMM)

AstraZenecaNCT07764978

Phase 3

A Phase III, Open-label, Multicentre, Randomised Study Comparing Consolidation Treatment With AZD0120, an Autologous Dual Targeting Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, Versus Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (TE NDMM) (DURGA-6)

The purpose of this study is to measure the efficacy of AZD0120 compared with ASCT in terms of progression-free survival (PFS) according to the International M…

Acute LeukemiaNewly DiagnosedRelapsed

AstraZenecaNCT07735637

Observational Study to Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia, Myelodysplastic Syndrome and Myelproliferative Neoplasms

The investigators are doing this research study to assess the percentage of patients receiving stem cell transplantation for the type of blood cancer you have.…

Memorial Sloan Kettering Cancer CenterNCT02677064

~$10 – $750

Multiple MyelomaNewly Diagnosed Multiple MyelomaTransplant Ineligible+1 more

ELDORADO: a Randomized Phase II Trial of Elranatamab or Daratumumab in Combination With Lenalidomide, Bortezomib, and Dexamethasone (RVd Lite) in Newly Diagnosed, Transplant Ineligible/Deferred Multiple Myeloma

This research study is being done to compare the efficacy and safety of the combination of elranatamab, lenalidomide, bortezomib, dexamethasone versus the comb…

Massachusetts General HospitalNCT07247097

~$10 – $6,250

Phase 1

A Phase I/II Study of an AAV-1 Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma

The goal of this clinical trial is to first define the Safety and Optimal Biological Dose (OBD) of study drug TGX-007 and to then further investigate the safet…

Glioblastoma (GBM)High Grade GliomasRecurrent Glioblastoma+1 more